Etnynodiol Diacetate

This review of the monograph ethynodiol diacetate (ED) include structural and molecular formulas molecular weight ED physical properties (melting point, optical rotation, and solubility) physical data (synonyms and trade names) and chemical and chemical and manufacture, use, appearance and analysis of ED. ED production is done by reducing ethindrone to ethynodiol which then product with acetic anhydride in pyridine the acetylated ED. ED is of course not known to occur. Applications in human medicine are similar to those of progesterone; It is mainly used in oral contraceptive, in combination with an estrogen and also used dysfunctional uterine bleeding, amenorrhea, and for the treatment of endometriosis; the French have to treat ED to treat advanced breast cancer. Analytical method for determining the ED than bulk chemicals are tabulated. The relevant biological data for the evaluation of carcinogenic risk to humans will be presented shortly. In laboratory experiments, ED has been tested in mice, rats and monkeys alone or in combination with an estrogen. ED product of mammary tumors in male mice castrated male rats. When combined with an estrogen, increases the incidence of pituitary tumors in mice, and malignant breast tumors in rats of both sexes. ED must be reported embryolethal for embryos before and postimiplantation and in some species have teratogenic effects. No human data are available, with the exception of studies on the COC, the side effects which may be attributed ED implicitly. Therefore, there is limited evidence of carcinogenicity of erectile dysfunction in animals and ED may be associated with an increased incidence of benign liver adenoma and decrease the incidence of benign breast disease associated with oral contraceptives with formulations together combined.